3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
33
Small Cell Lung Carcinoma
16
Breast Neoplasms
13
Sarcoma
10
Carcinoma, Hepatocellular
8
Esophageal Squamous Cell Carcinoma
7
Lung Neoplasms
6
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
5
Neoplasms
5
Carcinoma
5
Stomach Neoplasms
4
Pheochromocytoma
4
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Nasopharyngeal Carcinoma
4
Esophageal Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Ovarian Epithelial
4
Thyroid Neoplasms
3
Recurrence
3
Paraganglioma
3
NSCLC
3
Glioma
3
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Platinum-resistant Ovarian Cancer
2
Ovarian Diseases
2
Interventions
olaparib
1
niraparib
1
anlotinib
1
Trabectedin
1
Ocoxin
1
Dexamethasone
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adnexal Diseases
×
anlotinib
×
Clear all
NCT04566952
2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
68 enrolled